株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

牛呼吸器疾患(BRD)治療の世界市場:成長、動向、および予測

Bovine Respiratory Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 704741
出版日 ページ情報 英文 111 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.91円で換算しております。
Back to Top
牛呼吸器疾患(BRD)治療の世界市場:成長、動向、および予測 Bovine Respiratory Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 111 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

当レポートは世界の牛呼吸器疾患(BRD)治療について調査しており、市場機会や課題、成長および阻害要因、治療タイプ・疾患タイプ・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の仮定
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 治療タイプ別
    • ワクチン
    • 抗生物質
    • NSAID
    • 免疫調節薬
    • その他
  • 疾患タイプ別
    • 下気道感染症
    • 上気道感染症
    • ジフテリア
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Bayer AG
    • Bimeda
    • Boehringer Ingelheim GmbH
    • Ceva
    • Elanco
    • Merck & Co. Inc.
    • Vetoquinol
    • Virbac
    • Zoetis

第7章 市場機会および将来動向

目次
Product Code: 64390

The increasing consumption of beef and the rising population are the major factors that are driving the market studied. The increase in beef consumption is due to the rising population and increasing disposable income, across the world. Bovine Respiratory Disease (BRD) has a negative impact on both the dairy and beef industries, due to calf mortality, additional labor costs, and treatment expenses.

In addition, BRD adversely affects the reproductive performance, growth, and lifespan of cattle. Hence, there is a huge necessity for BRD treatment in the market. Moreover, to meet the increasing demand for beef, most of the countries in the world are increasing the production of cattle meat. The rising demand for beef, coupled with increased production of the same, leads to a growing emphasis on BRD treatment.

There are certain complexities that are associated with the diagnosis of the BRD. Animals suffering from BRD often show signs of depression, weight loss, cough, mucopurulent or purulent nasal discharge, fever, increased respiratory rate, and abnormal pulmonary sound on auscultation. The presumptive diagnosis after a physical examination is, however, difficult, owing to the similarities of clinical signs and variation of possible bacteria. Hence, the complex diagnostic procedure is restricting market growth.

Key Market Trends

Vaccines are Expected to Register Highest CAGR Over the Forecast Period

A vast range of bovine vaccines is available in the market for dairy and beef cattle to provide them protection against serious respiratory diseases. Klebsiella is a widespread pathogen that has been found to hamper dairy operations and has cost producers noteworthy losses. AgriLabs manufactured the first vaccine to prevent mastitis caused by Klebsiella pneumoni and this vaccine (KLEBVax SRP) is currently commercially available as announced on 23 July 2018 by the company. Hence, this cattle vaccine is expected to improve its market share in the coming years.

In April 2018, VIDO - InterVac announced about the development of a new vaccine to protect cattle in Africa against contagious bovine pleuropneumonia (CBPP), an infectious lung disease which has affected the livelihoods of approximately 24 million small-scale cattle farmers in Africa, causing more than USD 60 million yearly in losses. This type of research has brought about significant growth in the bovine vaccine market in developing regions.

Hence, it is believed that due to the availability of the vaccines and the company's focus on coming up with more of them, the vaccine segment will dominate the market with a highest CAGR over the forecast period.

North America to Dominate the Bovine Respiratory Disease Treatment Market

North America dominates the bovine respiratory disease treatment market, owing to the increasing domestic production, consumption, and export of bovine meat. According to the estimates of the United Nations Food and Agricultural Organization (UNFAO) for the year 2015-2016, America produced approximately 30 million tonnes of the meat, and it is expected to rise, owing to a rise in population. BRD is the most common endemic disease among North American feedlot cattle. According to the estimates of the Beef Cattle Research Council, BRD accounts for 65-80% of the morbidity and 45-75% of the mortality in the feedlots. Thus, the increasing consumption and production of bovine meat and rising cases of BRD are expected to propel the growth of the bovine respiratory disease treatment market in the region, over the forecast period.

Competitive Landscape

The market for bovine respiratory disease treatment is moderately competitive. There are few global players that are holding most of the market share. However, with the rising focus on veterinary health, various small companies are also coming up with novel therapeutics. Hence, it is expected that these companies will hold a substantial share of the market in the coming future.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of BRD (Bovine Respiratory Diseases)
    • 4.2.2 Increasing Consumption of Beef
    • 4.2.3 Changing Environmental Factors
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness about the Treatment of BRD in Developing and Underdeveloped Countries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Vaccines
    • 5.1.2 Antibiotics
    • 5.1.3 NSAIDs
    • 5.1.4 Immunomodulators
    • 5.1.5 Other Treatment Tyes
  • 5.2 By Diseases Type
    • 5.2.1 Lower Respiratory Tract Infections
    • 5.2.2 Upper Respiratory Tract Infections
    • 5.2.3 Diphtheria
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Bimeda
    • 6.1.3 Boehringer Ingelheim GmbH
    • 6.1.4 Ceva
    • 6.1.5 Elanco
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Vetoquinol
    • 6.1.8 Virbac
    • 6.1.9 Zoetis

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top